Blockbuster drug can lower your risk of heart attack by 13%
New York Post • • health
Key Points:
- Approximately 805,000 Americans experience heart attacks annually, with a rising incidence among those under 45, highlighting a growing public health concern.
- New research indicates that glucagon-like peptide‑1 receptor agonists (GLP-1 drugs), commonly used for weight loss, reduce the risk of major cardiovascular events by 13% over nearly three years of use.
- The study, involving over 90,000 patients, found that GLP-1 drugs also lower premature mortality and rates of non-fatal heart attacks and strokes, especially in individuals with high cardiovascular risk, type 2 diabetes, obesity, or existing heart disease.
- These findings emphasize the long-term cardiovascular benefits of GLP-1 receptor agonists and suggest potential for broader clinical use beyond current FDA approvals.
- GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are gaining attention not only for weight management but also for reducing risks of cancer, dementia, and substance abuse, indicating significant potential for preventive health strategies.
